upgrad outperform seem room
action revis estim introduc forecast
also upgrad santen neutral outperform rais target
price potenti return share price
remain around level six month await
catalyst rebound revis forecast albeit slightli
see opportun share price break extend slump
invest view earn firm expect profit
contribut japan new glaucoma treatment eyb
lenti comfort intraocular len cataract surgeri oversea market
santen continu benefit grow product line-up china led
glaucoma treatment europ record brisk sale former
merck product challeng re-enter us market toward
end santen partner local plan launch
preserflo microshunt glaucoma devic
hasten compani global expans also consolid
presenc nich market ophthalmolog
catalysts/risk focus particular domest demand
eyb lenti comfort news flow concern develop
us among santen rival global allergan novarti strength
ophthalm medicin busi europ believ compani
substanti opportun compet downsid risk includ heighten
concern loss momentum domest busi
reason loss japanes patent protect age-rel
macular degener drug eylea rx-to-otc switch hyalein
valuat target price base forward price-to-earnings
appli ep prev price-to-earnings appli
ep
valuat metric
chang tp
number share mn
price month
neutral outperform
price rel chart measur perform
topix close
spot exchang rate
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
price jun upsid rate neutral outperform target price
profit tax
issuanc retir stock
net chang cash
number share mn
earn firm present japan expect sale remain solid exist dri
eye drug diqua age-rel macular degener drug eylea
also anticip profit contribut new glaucoma treatment eyb
lenti comfort intraocular len cataract surgeri oversea market santen
continu benefit grow product line-up china led glaucoma treatment
europ record brisk sale former merck product
compani challeng re-enter us market toward end
partner us-bas plan launch preserflo microshunt de-
glaucoma devic santen subsequ plan seek us approv
launch eyb uveiti treatment sirolimu
hasten compani global expans also consolid presenc
nich market ophthalmolog glaucoma treatment eyb featur new
mechan alreadi approv launch japan accordingli consid
like get nod us well eu asia mileston
payment develop microshunt becom increasingli like
probabl increas cost lower overal op estim
influenc estim core op
profit tax
profit tax
cash equival
glaucoma ocular hypertens total
adjuv opthalm oper
intraocular len cataract treatment
eu prepar applic resubmiss
compani mention price
